ad
nonenvelop
doubl
strand
dna
viru
icosahedr
capsid
first
discov
row
colleagu
tri
cultur
adenoid
tissu
laboratori
ad
infect
usual
mild
human
be
sometim
could
life
threaten
especi
immunocompromis
individu
unit
state
armi
develop
live
ad
vaccin
prevent
acut
respiratori
diseas
caus
rosenfeld
et
al
develop
first
vivo
gene
transfer
use
ad
vector
demonstr
human
gene
deliv
ad
could
detect
lung
cotton
first
human
gene
therapi
studi
base
ad
perform
man
cystic
fibrosi
homozyg
receiv
first
vivo
gene
therapi
administr
rad
vector
express
normal
human
cftr
subsequ
clinic
studi
initi
recent
two
decad
ad
wide
appli
vaccin
carrier
sinc
capabl
elicit
b
cell
respons
furthermor
ad
genet
modifi
induc
apoptosi
cancer
cell
known
oncolyt
ad
gener
safe
replic
almost
live
cell
also
expand
easili
cell
purifi
cscl
gradient
ultracentrifug
administ
oral
intranas
intramuscular
rout
without
adjuv
review
ad
potenti
vaccin
develop
infecti
pathogen
cancer
treatment
address
latest
advanc
field
ad
isol
differ
mammalian
speci
human
bovin
simian
among
human
ad
chimpanze
ad
wide
use
laboratori
research
clinic
studi
human
ad
includ
serotyp
classifi
subtyp
g
chimpanze
ad
human
ad
distribut
widespreadli
natur
peopl
infect
thu
high
neutral
antibodi
titer
detect
among
human
subtyp
c
ad
common
ad
usual
infect
children
caus
upper
respiratori
tract
infect
urinari
tract
infect
human
subtyp
b
ad
sometim
caus
sever
eye
urinari
tract
infect
serotyp
subtyp
e
caus
acut
respiratori
howev
ad
infect
mild
promot
ad
vector
new
era
vaccin
carrier
ad
dna
viru
icosahedr
capsid
approxim
nm
diamet
sever
studi
illustr
structur
ad
cryoelectron
genom
dna
ad
kb
two
invert
termin
repeat
bp
flank
end
gene
express
life
cycl
ad
gener
divid
two
type
earli
gene
late
gene
earli
gene
includ
mainli
respons
facilit
replic
ad
chang
express
level
relat
host
gene
earli
gene
classifi
two
type
immedi
earli
gene
delay
earli
gene
promot
express
delay
earli
gene
protein
gener
suppress
apoptosi
host
cell
bind
bak
bax
late
gene
mainli
respons
lysi
host
cell
assembl
releas
virion
ad
virion
mainli
compris
two
type
protein
capsid
protein
core
protein
core
protein
mainli
includ
protein
v
vii
x
mainli
function
dnaassoci
protein
v
protein
mainli
contact
nucleoli
host
cell
involv
viral
assembl
vii
protein
play
key
role
manipul
dna
dna
bind
initi
dna
replic
viral
genom
protect
et
x
protein
respons
viral
chromosom
capsid
protein
compris
hexon
penton
fiber
iiia
viii
ix
trimer
hexon
surfac
ad
virion
hexon
major
structur
protein
hexon
sever
hypervari
region
major
neutral
site
ad
hypervari
region
replac
foreign
antigen
potenti
vaccin
pentam
penton
top
icosahedr
vertic
serv
receptor
ad
intern
host
vertex
trimer
fiber
protrud
capsid
surfac
mainli
respons
interact
cellular
receptor
initi
viral
iiia
protein
inner
capsid
surfac
mainli
respons
correct
viral
assembl
stabil
vertex
region
assembl
packag
vi
protein
insid
capsid
link
core
icosahedr
shell
critic
lytic
factor
ad
endosom
viii
protein
provid
bond
peripenton
hexon
involv
stabil
ix
protein
function
dampen
innat
immun
respons
affect
viral
tropism
stabil
mani
ad
engin
laboratori
clinic
use
recombin
ad
replicationincompet
replicationcompet
gene
essenti
replic
ad
total
partial
result
vector
infect
live
cell
expand
replicationincompet
normal
cell
howev
ad
propag
dedic
helper
cell
special
cell
provid
function
tran
hek
ad
replicationcompet
entri
ad
host
cell
initi
bind
fiber
knob
cell
receptor
car
function
receptor
fiber
protein
subtyp
cf
cell
cancer
cell
matur
skelet
muscl
cell
car
express
low
cardefici
lymphocyt
subtyp
c
ad
caus
latent
mutat
car
affect
tropism
ad
administ
result
suggest
might
receptor
ad
except
car
fact
mani
receptor
entri
ad
found
exampl
subtyp
b
sialic
acid
integrin
et
bind
fiber
knob
receptor
virion
intern
start
endocytosi
gener
endocytosi
initi
bind
penton
base
report
reveal
uptak
ad
virion
could
use
lipid
raft
caveola
entri
review
articl
suggest
ad
virion
coat
charg
polym
entri
routin
might
chang
ad
vector
one
effect
carrier
deliveri
foreign
antigen
host
cell
compar
viral
vector
lentiviru
retroviru
adenoassoci
viru
etc
ad
highli
immunogen
induc
robust
innat
adapt
immun
respons
mammalian
host
ad
larg
genom
size
make
manipul
genet
dna
much
conveni
unlik
lentiviru
retroviru
ad
integr
viral
genom
dna
host
genom
reduc
risk
insert
mutagenesi
adenoassoci
viru
less
pathogen
ad
yet
suitabl
mass
featur
make
ad
good
vaccin
carrier
infecti
diseas
tabl
tabl
show
list
vaccin
candid
base
ad
certain
infecti
diseas
earli
stage
ad
modifi
replicatingcompet
vector
delet
indispens
nowaday
ad
vector
replicationdefici
delet
vector
rescu
expand
transcompens
cell
line
delet
increas
packag
capac
ad
vector
ad
incorpor
kb
foreign
also
delet
vector
propag
cell
fulli
gut
ad
vector
develop
contain
replic
origin
packag
signal
viral
code
sequenc
delet
fulli
gut
ad
amplifi
appear
helper
compar
tradit
ad
vector
fulli
gut
ad
less
toxic
caus
cell
respons
transgen
product
stabli
differ
ad
vector
elicit
differ
immun
respons
variou
laboratori
anim
studi
siv
gagspecif
cell
respons
mice
vaccin
respect
demonstr
immunogen
gener
longliv
memori
cell
wherea
elicit
termin
differenti
phenotyp
anoth
studi
found
substanti
produc
higher
level
gamma
interferoninduc
protein
rhesu
base
differ
immunogen
profil
certain
serotyp
ad
select
altern
specif
research
ad
vector
administ
inject
oral
immun
elicit
well
immun
respons
oral
administr
elicit
mucosa
immun
respons
compar
inject
greatli
circumv
preexist
antivector
safe
effici
hiv
vaccin
urgent
need
sinc
hiv
still
remain
sever
public
health
threat
sever
strategi
develop
hiv
vaccin
design
ad
vector
wide
one
wellknown
clinic
trial
base
hiv
vaccin
develop
merck
clinic
trial
replicationincompet
vector
encod
gag
pol
nef
gene
administ
particip
dose
vp
placebo
administ
particip
vaccin
induc
cell
respons
homosexu
men
fail
prevent
hiv
infect
reduc
earli
viral
load
research
reveal
vaccin
appear
increas
risk
hiv
infect
serotyp
posit
explain
phenomenon
sever
studi
perform
suggest
one
possibl
mechan
immun
complex
antibodi
could
activ
dendrit
cell
might
serv
target
hiv
failur
merck
hiv
vaccin
trial
improv
strategi
test
regimen
dna
prime
boost
report
churchyard
gj
koup
ra
et
dna
plasmid
encod
multipl
hiv
gene
multipl
clade
prime
month
respect
dose
mg
express
multipl
hiv
gene
boost
month
induc
polyfunct
cell
well
antienvelop
bind
antibodi
reveal
heterolog
primeboost
regimen
potent
immun
strategi
induc
antibodi
cell
respons
howev
similar
strategi
use
anoth
clinic
trial
regimen
prime
mg
dna
encod
multipl
hiv
gene
week
respect
boost
pu
week
reduc
neither
rate
acquisit
viralload
set
point
base
vaccin
carrier
suitabl
hiv
prevent
serotyp
ad
base
vaccin
chimpanze
ad
vector
studi
express
envelop
new
vaccin
candid
posit
neg
particip
receiv
singl
intramuscular
immun
vp
result
reveal
elicit
system
mucos
envelopspecif
humor
cellular
immun
respons
interestingli
individu
preexist
neutral
antibodi
compar
immun
respons
neg
one
hiv
vaccin
base
express
envelop
antigen
phase
studi
healthi
hivuninfect
particip
recruit
divid
one
follow
group
person
person
placebo
group
particip
receiv
three
dose
mg
dna
one
dose
pu
rad
first
month
boost
pu
rad
month
week
post
boost
immun
respons
detect
result
indic
regimen
gener
well
toler
similarli
immunogen
elicit
crossclad
antibodi
respons
includ
envelop
igg
respons
present
novel
ad
vector
discov
develop
hiv
vaccin
design
none
readi
market
thu
improv
need
ad
vectorbas
hiv
vaccin
ad
vector
appli
develop
influenza
vaccin
adbas
influenza
vaccin
influenza
protein
ha
np
express
ad
vector
induc
neutral
antibodi
cell
respons
host
exampl
ha
protein
strain
express
ad
elicit
haspecif
antibodi
cellular
respons
besid
ad
vector
vaccin
particular
strain
influenza
viru
univers
influenza
vaccin
base
ad
explor
multival
influenza
vaccin
base
replicationincompet
differ
subtyp
np
one
subtyp
express
rad
mice
immun
intramuscularli
pfu
rad
twice
interv
week
post
boost
high
level
humor
cellular
immun
respons
well
induc
mice
protect
lethal
challeng
avian
influenza
viru
anoth
multival
influenza
vaccin
base
ha
gene
subtyp
influenza
viru
express
ad
vector
immun
mice
regimen
dose
rang
vp
week
interv
vaccin
result
reveal
highest
dose
vaccin
group
protect
heterolog
lethal
challeng
differ
subtyp
influenza
viru
indic
adbas
multival
influenza
vaccin
great
potenti
prevent
control
influenza
viru
adbas
influenza
vaccin
test
clinic
trial
nonrepl
vector
express
ha
avian
influenza
ligand
test
particip
receiv
one
dose
ad
capsul
titer
rang
iu
boost
anoth
dose
iu
ad
week
post
prime
vaccin
result
reveal
antigen
specif
cytotox
respons
induc
dose
depend
manner
cytotox
respons
increas
boost
demonstr
adbas
vaccin
administ
oral
could
induc
antigen
specif
immun
respons
safe
vaccin
base
avian
influenza
vaccin
develop
test
clinic
trial
express
ha
oral
administ
time
dose
vp
within
day
boost
inactiv
virus
result
demonstr
cellular
immun
respons
well
induc
oral
administr
ad
might
enhanc
efficaci
poorli
immunogen
vaccin
limit
studi
hi
titer
hardli
oral
administ
replicationcompet
vaccin
anoth
improv
strategi
studi
individu
prime
three
time
dose
vp
day
boost
unadjuv
licens
inactiv
subunit
vaccin
month
new
regimen
induc
high
hi
titer
compar
unprim
individu
compens
disadvantag
previou
vaccin
routin
develop
rnai
technolog
ad
base
rnai
strategi
appli
prevent
control
influenza
infect
exampl
novel
chimpanze
ad
term
use
microrna
express
vector
test
mice
amirna
target
np
gene
influenza
viru
could
effici
suppress
viral
replic
confer
complet
protect
lethal
challeng
ebola
viru
firstli
discov
outbreak
democrat
republ
congo
outbreak
africa
made
public
concern
sever
strategi
ebola
vaccin
develop
ad
vector
select
prioriti
nih
vaccin
research
center
firstli
develop
vaccin
base
heterolog
primeboost
regimen
research
primat
firstli
immun
dna
vaccin
three
time
week
dose
mg
boost
pfu
express
gp
protein
ebola
viru
week
post
prime
result
show
high
antibodi
titer
cell
respons
induc
vaccin
anim
vaccin
group
higher
surviv
rate
control
group
challeng
ebola
sinc
experi
took
six
month
complet
immun
flow
chart
research
develop
acceler
immun
method
acceler
experi
anim
given
express
gp
np
ebola
viru
twice
dose
vp
interv
vaccin
anim
challeng
lethal
ebola
viru
protect
highli
effect
sinc
ebolaspecif
cell
antibodi
respons
well
induc
subsequ
studi
anim
prime
challeng
day
later
still
high
surviv
rate
either
low
high
dose
challeng
viru
ebola
vaccin
show
good
prospect
nonhuman
primat
first
clinic
trial
base
recombin
vaccin
encod
envelop
gp
zair
sudan
ebola
viru
test
random
placebocontrol
doubleblind
phase
human
studi
thirtyon
healthi
adult
receiv
singl
dose
vp
n
vp
n
placebo
n
result
indic
antibodi
respons
two
gp
subject
well
balanc
low
dose
group
antibodi
respons
zair
gp
sudan
gp
howev
antibodi
respons
high
dose
group
respect
studi
preexist
neutral
antibodi
also
note
nt
appear
affect
cell
respons
ebola
gp
sinc
subject
respond
cell
recent
ebola
vaccin
base
serotyp
develop
one
chimpanze
ad
serotyp
clinic
trial
base
ebola
vaccin
volunt
recruit
divid
group
volunt
group
receiv
rad
express
gp
protein
zair
sudan
ebola
viru
one
group
receiv
high
titer
ad
vp
anoth
receiv
vp
two
individu
high
dose
group
experienc
transient
fever
final
result
demonstr
rad
induc
well
specif
antibodi
respons
tcell
respons
higher
level
respons
high
dose
anoth
trial
base
volunt
divid
group
receiv
singl
dose
ad
rang
vp
vp
volunt
develop
transient
fever
vaccin
specif
antibodi
respons
tcell
respons
success
elicit
level
lower
detect
nonhuman
recent
phase
clinic
trial
perform
oct
feb
particip
mali
usa
recruit
receiv
express
gp
ebola
singl
dose
rang
pu
prime
ad
malian
boost
vaccinia
ankara
express
gp
zair
ebola
viru
filoviru
antigen
mvabnphyllo
vaccin
result
show
pu
singledos
rad
could
suffic
efficaci
trial
regimen
mvabnphyllo
boost
could
confer
longliv
protect
might
need
healthcar
ad
vector
vaccin
develop
infecti
diseas
besid
influenza
viru
hiv
ebola
viru
tetraval
dengu
viru
vaccin
base
rad
test
nonhuman
primat
studi
prm
e
gene
differ
subtyp
dengu
viru
express
ad
vaccin
includ
two
dose
iu
rad
administr
interv
day
day
post
prime
anim
challeng
dengu
viru
vaccin
result
reveal
anim
produc
hightit
antibodi
could
neutral
four
serotyp
dengu
virus
vitro
challeng
studi
show
signific
protect
viremia
observ
four
dengu
viru
serotyp
protect
efficaci
better
challeng
addit
adbas
viru
vaccin
ad
develop
bacteria
vaccin
protozoan
vaccin
mycobacterium
tuberculosi
caus
seriou
bacteri
infect
human
vaccin
base
express
test
phase
clinic
trial
result
show
polyfunct
cell
respons
well
stimul
preexist
neutral
antibodi
littl
influenc
potenc
malaria
caus
plasmodium
falciparum
pose
seriou
threat
public
health
vector
encod
apic
membran
antigen
circumsporozoit
protein
p
falciparum
evalu
clinic
studi
dna
prime
ad
boost
regimen
prove
effect
elicit
specif
cell
respons
furthermor
serotyp
ad
develop
malaria
vaccin
list
tabl
human
ad
serotyp
extens
use
vaccin
develop
mainli
due
excel
immunogen
safeti
effect
preexist
immun
vaccin
clinic
use
greatli
limit
rare
human
serotyp
ad
nonhumanorigin
ad
chimpanze
ad
extens
test
preclin
research
clinic
trial
oncolyt
ad
shown
great
promis
cancer
treatment
sinc
exhibit
distinct
anticanc
characterist
life
cycl
ad
adinfect
cancer
cell
lyse
end
releas
ad
virion
infect
cancer
cell
initi
next
life
cycl
gener
two
strategi
wide
adopt
modif
oncolyt
ad
first
one
includ
ad
express
therapeut
gene
combin
rnai
technolog
degrad
tumor
promot
protein
second
one
mainli
focus
capsid
modif
ad
make
ad
specif
tropism
tumor
cell
replic
higher
titer
tumor
tissu
normal
one
two
strategi
might
integr
gener
better
anticanc
effect
one
wellknown
adbas
anticanc
drug
vector
express
drive
cmv
promot
region
advexin
appli
multipl
cancer
treatment
head
neck
cancer
breast
cancer
colon
cancer
et
hand
neck
squamou
cell
carcinoma
advexin
test
phase
iii
clinic
trial
patient
randomli
treat
either
intratumor
day
week
daili
dose
vp
methotrex
weekli
start
dose
treatment
cycl
includ
day
result
reveal
vector
well
toler
antitumor
activ
anoth
wellknown
drug
glioma
sitimagen
ceradenovec
drug
vaccin
express
herp
simplex
viru
thymidin
kinas
downstream
cmv
promot
cassett
phase
iii
trial
patient
recruit
group
standard
care
group
differ
group
receiv
standard
care
plu
inject
vp
rad
standard
care
alon
almost
individu
experienc
advers
event
trial
clinic
result
suggest
use
sitimagen
ceradenovec
increas
surviv
time
reintervent
patient
newli
diagnos
supratentori
glioblastoma
transduct
specif
tumor
antigen
dendrit
cell
one
effect
strategi
cancer
vitro
studi
dc
transduc
rad
express
livin
induc
strong
specif
cytotox
lymphocyt
differ
cancer
ad
arm
immun
modul
gmcsf
reic
induc
cytotox
lymphocyt
cancer
clinic
trial
patient
receiv
combin
treatment
adgmcsf
alkyl
agent
higher
surviv
rate
one
treat
alkyl
agent
possibl
due
activ
antitumor
tumorxenograft
mous
model
adreic
induc
tumorassoci
antigen
specif
cytotox
tlymphocyt
secret
reic
protein
tumor
gener
proper
microenviron
induc
activ
dendrit
cell
result
decreas
tumor
size
tumorbear
mice
receiv
adreic
compar
control
rnai
technolog
wide
use
downregul
specif
gene
express
sequencespecif
degrad
risc
applic
rnai
technolog
base
ad
may
extrem
effect
sinc
small
rna
molecul
steadili
express
thu
target
protein
remain
low
level
long
one
firstli
use
rnai
technolog
base
ad
vascular
endotheli
growth
factor
vegf
specif
target
small
rna
induc
maintain
longlast
silenc
vegf
studi
construct
ad
shvegf
express
region
drive
promot
vaccin
adshvegf
tumorbear
mice
potent
antiangiogenesi
induc
result
tumor
suppress
surviv
recent
studi
reveal
amirna
base
vector
could
downregul
survivin
highli
express
tumor
caus
blockad
mitosi
cell
cycl
arrest
phase
tumorxenograft
nude
mice
model
survivintarget
amirna
express
effect
delay
growth
hepatocellular
cervic
ad
great
potenti
anticanc
vector
howev
clinic
use
ad
limit
due
limit
infect
cancer
cell
modifi
tropism
ad
altern
way
gener
better
anticanc
effect
recent
studi
epiderm
growth
factorlik
domain
human
hrg
insert
hi
loop
fiber
without
advers
effect
ad
growth
yield
fibermodifi
ad
virion
show
enhanc
infect
cell
express
cognat
receptor
chines
hamster
ovari
cho
cell
could
transduc
hrgmodifi
viru
wild
type
studi
show
fibermodifi
ad
specif
tropism
differ
cancer
cell
may
provid
new
strategi
ad
base
cancer
common
method
ad
vaccin
develop
express
foreign
antigen
region
ad
vector
previous
describ
tabl
tabl
howev
preexist
antibodi
vector
may
result
failur
vaccin
antigen
capsidincorpor
strategi
develop
compens
drawback
associ
convent
antigenexpress
system
ad
vector
evad
preexisit
immun
ad
capsid
protein
hexon
penton
base
fiber
pix
variabl
site
antigen
hexon
abund
structur
protein
capsid
sever
hypervari
region
modifi
display
foreign
antigen
without
affect
ad
rescu
infect
exampl
vector
modifi
express
linear
bcell
epitop
ectodomain
matrix
influenza
viru
within
hypervari
region
ad
hexon
addit
vector
wildtyp
hexon
influenza
viru
np
transgen
product
region
also
test
studi
vaccin
regimen
includ
prime
vp
rad
mice
boost
month
later
preclin
studi
demonstr
ad
express
within
hexon
induc
higher
magnitud
avid
antibodi
respons
carri
within
vector
express
part
transgen
product
antibodi
respons
could
boost
second
dose
hexonmodifi
vector
repeat
immun
hexonmodifi
besid
influenza
viru
vaccin
studi
report
insert
neutral
epitop
hfmd
viru
hexon
could
elicit
neutral
antibodi
hfmd
viru
lethal
challeng
mice
hvr
hexon
contain
neutral
epitop
hexonmodifi
ad
might
chang
immunogen
compar
wild
type
ad
antisera
hexonmodifiedad
vaccin
anim
well
neutral
wild
type
ad
provid
good
platform
primeboost
regimen
ad
base
besid
hexon
fiber
engin
antigendisplay
system
fiber
modif
make
ad
specif
tropism
cancer
cell
describ
incorpor
foreign
antigen
vaccin
infecti
diseas
well
vector
express
pseudomona
aeruginosa
immunedomin
outer
membran
protein
f
oprf
epitop
five
distinct
site
fiber
immun
mice
result
demonstr
fgloop
hiloop
insert
site
better
insert
site
fiber
sinc
higher
level
protect
immun
p
aeruginosa
induc
fgloop
hiloop
modifi
penton
base
pix
test
antigenincorpor
howev
compar
three
protein
capsid
penton
base
rare
incorpor
foreign
antigen
perhap
due
structur
constraint
gener
ad
vector
easi
manipul
genet
modif
capabl
induc
potent
antigenspecif
immun
respons
ad
speci
rare
pathogen
human
compar
convent
vaccin
ad
vectorbas
vaccin
express
wide
rang
antigen
viru
bacteria
protozoan
elicit
longterm
immun
respons
infecti
diseas
despit
preexist
neutral
antibodi
human
ad
rare
serotyp
ad
differ
speci
develop
circumv
disadvantag
advantag
make
ad
attract
potenti
vaccin
candid
furthermor
ad
vector
show
prioriti
anticanc
research
sinc
arm
therapeut
gene
modifi
expand
higher
titer
tumor
normal
tissu
mani
ad
vector
studi
anim
either
infecti
diseas
cancer
reveal
good
prospect
develop
despit
incomplet
success
adbas
vaccin
ad
vector
still
show
great
potenti
extens
test
clinic
trial
recent
inform
obtain
adrel
clinic
trial
understand
ad
vector
greatli
enlarg
promot
use
ad
vector
prevent
control
infecti
diseas
cancer
